Psychologists have a strong preference for measuring human attributes (emotions, behavioral repertoires, cognitive appraisals) as dimensional continuities, routinely testing for differences with a Fisherian null hypothesis procedure to detect mean difference. The importance of that difference has often been of secondary concern. There have been plenty of dissenting voices [1, 9, 20] , but old habits die hard. One consequence of this is that the evaluation of treatment effectiveness, at least since Smith and Glass's pioneering meta-analysis [14] , has been expressed as an effect size: the magnitude of differences between 2 groups expressed as a ratio of their variance. There are 2 points to note. First, the effect size is a statistical measure devoid of any additional meaning; in and of itself, it has no external referent. Second, it is difficult to express the benefits of a treatment in a way that is readily understandable to patients or even to other stakeholders. An effect size of 0.8, an omnibus value for psychological treatments [19] , is the 79th percentile of the control group. An effect size of around 0.2, a current estimate for psychological treatments of pain, corresponds to the 58th percentile [10] . This is difficult to communicate because it does not correspond to the patient's reasonable enquiry: ''How many people get better?'' In this case, counting to 2 (better vs not better) might be a strategy to be preferred to divining subtle between group differences.
Few trials of psychological interventions count to 2. Where they have done so, the tendency has been to dichotomize a continuous measure [16] . This problem is not unique to psychological measures. There is a copious literature on dichotomizing and categorizing continuous measures of pain. Valid cut scores for mild, moderate, and severe pain are established by testing the association of pain scores with indices of functional performance [3, 5, 12] . In this issue of PAIN Ò , Sil et al. [13] report a secondary analysis of trial data where the original hypothesis was that a cognitive-behavioral therapy intervention would be significantly more effective than education in reducing the primary outcome of functional disability in children with juvenile fibromyalgia-that is, an hypothesis of difference in means [8] . The immediate posttreatment effect gave an impressive uncorrected effect size of 0.78 (data in Table 2 Step 1 establishes the magnitude of change required for the change to be beyond that attributable to measurement error. This smallest detectable value is a statistical criterion for measurement precision, not a clinical criterion. The setting of clinical criteria is more problematic and varied. The method of Jacobson et al. uses the statistical properties of the measure to set 3 possible cut points. For 2 cut points, data from a nonclinical reference sample is required. The third cut point relies solely on the distribution of the clinical group. Each cut point categorizes the individual in reference to his or her relative position in the group. The cut points are determined by statistical criteria intrinsic to the measure. The validity of the interpretation depends on the likely assignment to group membership. As such, it may tell us little about other parameters likely to be of clinical or social importance, such as probability of relapse. This study takes a slightly different approach to defining clinical significance for the Functional Disability Inventory (FDI). They use cut points established in a prior analysis of data from 1300 children with a variety of pain disorders [7] . That study set cut points at the upper and lower quartiles of the distribution, to give 3 groups (no/ minimal, moderate, and severe disability) validating the classification by correlating FDI scores with pain intensity. This is ironic given the history of validating pain scores by reference to function. Arguably, validation of a measure for clinical significance would be better established using operations of convergent validity, ie, other measures of function. The analysis of the FDI of Kashikar-Zuck et al. [7] showed that mean disability increased with age and that there were slight differences between clinical groups in FDI scoreinformation not used in the Sil et al. analysis.
There are many advantages in using the distributional properties of scales in outcome trials. Our use of them would be aided by the development of high-quality norms, including parameters such as age, sex, diagnostic group (including nonclinical subjects), and country, which capture known variation in data [11, 17] . Larger samples, obtained by combining data sets with meta-analytic techniques will give more accurate estimates and better prediction for individuals. The work of IMMPACT [2, 15, 18] has focused attention on the need rationalize the plethora of measures used and this should facilitate the selection of measures for further development. Validation, especially with regard to establishing meaningful clinical cut points, ie, those that enable us to make good clinical decisions, is an ongoing requirement. We need to be able to count to 2, but we also need to capture the subtlety and variation in human behavior.
Note
The title is a quotation from George W. Pickering's High Blood Pressure (2nd ed.; London: J&A Churchill, 1968) 
